New Zealand markets closed

C4 Therapeutics, Inc. (CCCC)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
6.72-0.19 (-2.75%)
At close: 04:00PM EDT
6.72 0.00 (0.00%)
After hours: 07:10PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 473.34M
Enterprise value 290.64M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)16.50
Price/book (mrq)1.92
Enterprise value/revenue 14.00
Enterprise value/EBITDA -2.27

Trading information

Stock price history

Beta (5Y monthly) 3.19
52-week change 3110.03%
S&P500 52-week change 321.23%
52-week high 311.88
52-week low 31.06
50-day moving average 38.46
200-day moving average 34.55

Share statistics

Avg vol (3-month) 32.72M
Avg vol (10-day) 31.31M
Shares outstanding 568.6M
Implied shares outstanding 668.6M
Float 852.5M
% held by insiders 111.62%
% held by institutions 176.66%
Shares short (28 Mar 2024) 49.15M
Short ratio (28 Mar 2024) 43.24
Short % of float (28 Mar 2024) 418.92%
Short % of shares outstanding (28 Mar 2024) 413.34%
Shares short (prior month 29 Feb 2024) 42.97M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,147.71%

Management effectiveness

Return on assets (ttm)-21.53%
Return on equity (ttm)-49.50%

Income statement

Revenue (ttm)20.76M
Revenue per share (ttm)0.42
Quarterly revenue growth (yoy)14.30%
Gross profit (ttm)N/A
EBITDA -137.15M
Net income avi to common (ttm)-132.49M
Diluted EPS (ttm)-2.67
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)253.68M
Total cash per share (mrq)3.7
Total debt (mrq)70.98M
Total debt/equity (mrq)28.84%
Current ratio (mrq)6.34
Book value per share (mrq)4.07

Cash flow statement

Operating cash flow (ttm)-106.84M
Levered free cash flow (ttm)-66.06M